{"id":23160,"date":"2025-05-13T07:15:14","date_gmt":"2025-05-13T07:15:14","guid":{"rendered":"https:\/\/www.hotelsalepage.com\/feed\/cision-pr-newswire\/gi-innovation-and-gi-biome-advance-to-the-semi-finals-of-xprize-healthspan-with-anti-aging-potential-of-gi-102-and-gib-7-combination-therapy\/"},"modified":"2025-05-13T07:15:14","modified_gmt":"2025-05-13T07:15:14","slug":"gi-innovation-and-gi-biome-advance-to-the-semi-finals-of-xprize-healthspan-with-anti-aging-potential-of-gi-102-and-gib-7-combination-therapy","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=23160","title":{"rendered":"GI Innovation and GI Biome Advance to the Semi-finals of XPRIZE Healthspan with Anti-Aging Potential of GI-102 and GIB-7 Combination Therapy"},"content":{"rendered":"<ul type=\"disc\">\n<li><b>GI Innovation and GI Biome have\u00a0<\/b><b>been selected as a Top 40<\/b><b>\u00a0semi-<\/b><b>finalist in<\/b><b>\u00a0the XPRIZE Healthspan competition<\/b><b>\u00a0among 600 registered teams from 58 countries<\/b><\/li>\n<li><b>Selected as one of 8 teams to pitch at the\u00a0XPRIZE Investor Summit in <span class=\"xn-location\">New York<\/span><\/b><\/li>\n<li><b>The team is now competing for\u00a0<\/b><b>one of <\/b><b>the largest prize <\/b><b>pool<\/b><b>s<\/b><b> in the history of <\/b><b>XPRIZE<\/b>\u00a0\u00a0\u00a0\u00a0<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, May 13, 2025 \/PRNewswire\/ &#8212; <a href=\"https:\/\/www.gi-innovation.com\/en\/\" target=\"_blank\" rel=\"nofollow\">GI Innovation<\/a>, a South Korean biotech company, announced on <span class=\"xn-chron\">May 13<\/span> that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company GI Biome.<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2685816\/Milestone_1_Winners_of_the_XPRIZE_Healthspan_at_the_Awards_Ceremony.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2685816\/Milestone_1_Winners_of_the_XPRIZE_Healthspan_at_the_Awards_Ceremony.jpg?p=medium600\" title=\"Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony\" alt=\"Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony\" \/> <\/a> <br \/><span>Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony<\/span><\/p>\n<\/div>\n<p>The XPRIZE Healthspan semi-finals ceremony is taking place in <span class=\"xn-location\">New York<\/span> from <span class=\"xn-chron\">May 12 to 14<\/span>, with the top 40 semi-finalist teams out of more than 600 registered teams among 58 countries invited. The company has not only advanced to the semi-finals but has also been selected as one of 8 teams among the 40 semi-finalists to earn an exclusive opportunity to present its vision and innovations to high-profile, institutional global investors.<\/p>\n<p>XPRIZE, a U.S.-based nonprofit foundation, is the recognized global leader in designing and executing large-scale competitions to solve humanity&#8217;s greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future.\u00a0<\/p>\n<p>Semi-finalists are selected by an expert committee using rigorous guidelines and advancement into this elite group is seen as recognition of exceptional scientific vision and execution.<\/p>\n<p>The XPRIZE Healthspan competition, in which the joint GI Innovation &#8211; GI Biome team is competing, aims to discover breakthrough treatments that can slow or prevent age-related degeneration. The competition offers a record-breaking total prize pool of approximately USD <span class=\"xn-money\">$101 million<\/span>.<\/p>\n<p>Selected as a semi-finalist team, GI Innovation will receive a prize of USD <span class=\"xn-money\">$250,000<\/span> to support the next clinical trial stage. Only the top 10 teams from the semi-finals round will advance to the grand finals.<\/p>\n<p><b>&#8216;Anti-Aging&#8217; Strategy with Immune Booster GI-102 and\u00a0Microbiome-Based GIB-7 Combination<\/b><\/p>\n<p>The GI Innovation-GI Biome joint team proposed a combination therapy consisting of GI-102, an immune-boosting drug, and GIB-7, a microbiome-based synbiotic, as a novel anti-aging approach.<\/p>\n<p>Clinical studies have shown that GI-102 potently activates CD8+ T cells and NK cells at high doses, allowing those immune cells to safely attack a range of tumor types including melanoma, kidney, lung and bladder cancers. However, at a low dose, it selectively expands and activates NK cells, which are critical for clearing senescent cells and cellular debris, playing a vital role in delaying aging and maintaining physiological functions. Based on this mechanism, GI Innovation is pursuing the use of low-dose GI-102 as an NK cell enhancer.<\/p>\n<p>GIB-7 is a premium synbiotic developed using GI Biome&#8217;s proprietary Microbiome+ Herbal Therapy platform. It combines three patented probiotic strains with herbal ingredients. Clinical trials in elderly volunteers at Seoul <span class=\"xn-org\">National University<\/span> Hospital have already been completed. In an aging mouse model, GIB-7 elicited an increase in beneficial gut microbiota, improved regulation of circadian rhythm, and improved muscle strength.<\/p>\n<p>&#8220;We entered this competition with the goal of winning, and it is a great honor to have passed the first gateway, highlighting the scientific innovation of both GI Innovation and GI Biome,&#8221; said Dr. <span class=\"xn-person\">Myoung-Ho Jang<\/span>, CEO and Founder of GI Innovation. &#8220;The upcoming clinical trial will be conducted in collaboration with Dr. Katherine Samaras, a key opinion leader in anti-aging research at the Garvan Institute of Medical Research in <span class=\"xn-location\">Australia<\/span>. Through this competition, we will do our utmost to realize our global vision of progressing from treatment to prevention.&#8221;<\/p>\n<p>\u00a0<\/p>","protected":false},"excerpt":{"rendered":"<p><!-- wp:html --><\/p>\n<ul type=\"disc\">\n<li><b>GI Innovation and GI Biome have\u00a0<\/b><b>been selected as a Top 40<\/b><b>\u00a0semi-<\/b><b>finalist in<\/b><b>\u00a0the XPRIZE Healthspan competition<\/b><b>\u00a0among 600 registered teams from 58 countries<\/b><\/li>\n<li><b>Selected as one of 8 teams to pitch at the\u00a0XPRIZE Investor Summit in <span class=\"xn-location\">New York<\/span><\/b><\/li>\n<li><b>The team is now competing for\u00a0<\/b><b>one of <\/b><b>the largest prize <\/b><b>pool<\/b><b>s<\/b><b> in the history of <\/b><b>XPRIZE<\/b>\u00a0\u00a0\u00a0\u00a0<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">SEOUL, South Korea<\/span>, May 13, 2025 \/PRNewswire\/ &#8212; <a href=\"https:\/\/www.gi-innovation.com\/en\/\" target=\"_blank\" rel=\"nofollow\">GI Innovation<\/a>, a South Korean biotech company, announced on <span class=\"xn-chron\">May 13<\/span> that it has been selected as a semi-finalist in the XPRIZE Healthspan competition in collaboration with its sister company GI Biome.<\/span><\/p>\n<div class=\"PRN_ImbeddedAssetReference\">\n<p> <a href=\"https:\/\/mma.prnasia.com\/media2\/2685816\/Milestone_1_Winners_of_the_XPRIZE_Healthspan_at_the_Awards_Ceremony.html\" target=\"_blank\" rel=\"nofollow\"> <img decoding=\"async\" src=\"https:\/\/mma.prnasia.com\/media2\/2685816\/Milestone_1_Winners_of_the_XPRIZE_Healthspan_at_the_Awards_Ceremony.jpg?p=medium600\" title=\"Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony\" alt=\"Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony\" \/> <\/a> <br \/><span>Milestone 1 Winners of the XPRIZE Healthspan at the Awards Ceremony<\/span><\/p>\n<\/div>\n<p>The XPRIZE Healthspan semi-finals ceremony is taking place in <span class=\"xn-location\">New York<\/span> from <span class=\"xn-chron\">May 12 to 14<\/span>, with the top 40 semi-finalist teams out of more than 600 registered teams among 58 countries invited. The company has not only advanced to the semi-finals but has also been selected as one of 8 teams among the 40 semi-finalists to earn an exclusive opportunity to present its vision and innovations to high-profile, institutional global investors.<\/p>\n<p>XPRIZE, a U.S.-based nonprofit foundation, is the recognized global leader in designing and executing large-scale competitions to solve humanity&#8217;s greatest challenges. For over 30 years, our unique model has democratized crowd-sourced innovation and scientifically scalable solutions that accelerate a more equitable and abundant future.\u00a0<\/p>\n<p>Semi-finalists are selected by an expert committee using rigorous guidelines and advancement into this elite group is seen as recognition of exceptional scientific vision and execution.<\/p>\n<p>The XPRIZE Healthspan competition, in which the joint GI Innovation &#8211; GI Biome team is competing, aims to discover breakthrough treatments that can slow or prevent age-related degeneration. The competition offers a record-breaking total prize pool of approximately USD <span class=\"xn-money\">$101 million<\/span>.<\/p>\n<p>Selected as a semi-finalist team, GI Innovation will receive a prize of USD <span class=\"xn-money\">$250,000<\/span> to support the next clinical trial stage. Only the top 10 teams from the semi-finals round will advance to the grand finals.<\/p>\n<p><b>&#8216;Anti-Aging&#8217; Strategy with Immune Booster GI-102 and\u00a0Microbiome-Based GIB-7 Combination<\/b><\/p>\n<p>The GI Innovation-GI Biome joint team proposed a combination therapy consisting of GI-102, an immune-boosting drug, and GIB-7, a microbiome-based synbiotic, as a novel anti-aging approach.<\/p>\n<p>Clinical studies have shown that GI-102 potently activates CD8+ T cells and NK cells at high doses, allowing those immune cells to safely attack a range of tumor types including melanoma, kidney, lung and bladder cancers. However, at a low dose, it selectively expands and activates NK cells, which are critical for clearing senescent cells and cellular debris, playing a vital role in delaying aging and maintaining physiological functions. Based on this mechanism, GI Innovation is pursuing the use of low-dose GI-102 as an NK cell enhancer.<\/p>\n<p>GIB-7 is a premium synbiotic developed using GI Biome&#8217;s proprietary Microbiome+ Herbal Therapy platform. It combines three patented probiotic strains with herbal ingredients. Clinical trials in elderly volunteers at Seoul <span class=\"xn-org\">National University<\/span> Hospital have already been completed. In an aging mouse model, GIB-7 elicited an increase in beneficial gut microbiota, improved regulation of circadian rhythm, and improved muscle strength.<\/p>\n<p>&#8220;We entered this competition with the goal of winning, and it is a great honor to have passed the first gateway, highlighting the scientific innovation of both GI Innovation and GI Biome,&#8221; said Dr. <span class=\"xn-person\">Myoung-Ho Jang<\/span>, CEO and Founder of GI Innovation. &#8220;The upcoming clinical trial will be conducted in collaboration with Dr. Katherine Samaras, a key opinion leader in anti-aging research at the Garvan Institute of Medical Research in <span class=\"xn-location\">Australia<\/span>. Through this competition, we will do our utmost to realize our global vision of progressing from treatment to prevention.&#8221;<\/p>\n<p>\u00a0<\/p>\n<p><!-- \/wp:html --><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-23160","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23160","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=23160"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/23160\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=23160"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=23160"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=23160"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}